comprehensive -WSS

comprehensive

author：focus 2025-10-02 10:48:15 - browse：63538

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Helping hospitals and community health centers plan for resilience

hotspot

WSS

A cyberattack has disrupted hospitals and health care in several states

Second House panel advances two

ProMED, early warning system on disease outbreaks, in peril

Microsoft strikes partnership with Duke Health to advance health AI

2 US Navy sailors arrested for allegedly spying for China

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

entertainment

comprehensive

knowledge

Continuity nursing helped my family in our darkest PICU moments

Military medical care influenced by rank and race, new study finds

Virginia high school admissions case could be legal follow

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Sports medicine is finally prioritizing gender equality

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Anesthesiologist group: stop taking Ozempic before surgery

A cyberattack has disrupted hospitals and health care in several states

Activists slam private health insurers over coverage restrictions

White House drug shortage group privately met with industry

knowledge

Case highlights the risks of experimental stem cell therapy

White House drug shortage group privately met with industry

Humana, CVS hope to turn members into patients at clinics

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

2 US Navy sailors arrested for allegedly spying for China

It's time to retire 'poor historian' from clinicians' vocabularies

knowledge

hotspot

focus

explore